Abstract
Although pneumococcal vaccine has been recommended for patients with chronic obstructive pulmonary disease (COPD), its efficacy in this population has not been shown. A double-blind randomized controlled trial of 14-valent pneumococcal vaccine was carried out in 189 men and women aged 40 to 89 years with a clinical diagnosis of COPD and a forced expiratory volume in 1 second of less than 1.5 L. Of the 189, 92 received the vaccine and 97 received saline placebo. In a randomly chosen subsample of those who received the vaccine the mean titres of specific IgG antibody to selected pneumococcal polysaccharide serotypes increased two- to threefold by 4 weeks after vaccination. Over a 2-year period the rates of death, hospital admissions and emergency visits and the mean length of hospital stay were not significantly different in the two groups. Although a protective effect of 14-valent pneumococcal vaccine could not be shown, the small size of the sample and the relatively low follow-up rates preclude firm conclusions about efficacy from these data alone. The elevated antibody levels before vaccination in some of the patients, suggesting prior infection with Diplococcus pneumoniae, may partly explain the findings.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Anthonisen N. R., Wright E. C., Hodgkin J. E. Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1986 Jan;133(1):14–20. doi: 10.1164/arrd.1986.133.1.14. [DOI] [PubMed] [Google Scholar]
- Austrian R. A reassessment of pneumococcal vaccine. N Engl J Med. 1984 Mar 8;310(10):651–653. doi: 10.1056/NEJM198403083101010. [DOI] [PubMed] [Google Scholar]
- Austrian R., Douglas R. M., Schiffman G., Coetzee A. M., Koornhof H. J., Hayden-Smith S., Reid R. D. Prevention of pneumococcal pneumonia by vaccination. Trans Assoc Am Physicians. 1976;89:184–194. [PubMed] [Google Scholar]
- Burrows B., Earle R. H. Prediction of survival in patients with chronic airway obstruction. Am Rev Respir Dis. 1969 Jun;99(6):865–871. doi: 10.1164/arrd.1969.99.6.865. [DOI] [PubMed] [Google Scholar]
- Filice G. A., Darby C. P., Fraser D. W. Pneumococcal bacteremia in Charleston County, South Carolina. Am J Epidemiol. 1980 Dec;112(6):828–835. doi: 10.1093/oxfordjournals.aje.a113055. [DOI] [PubMed] [Google Scholar]
- Landesman S. H., Smith P. M., Schiffman G. Pneumococcal vaccine in elderly patients with COPD. Chest. 1983 Oct;84(4):433–435. doi: 10.1378/chest.84.4.433. [DOI] [PubMed] [Google Scholar]
- Mufson M. A., Oley G., Hughey D. Pneumococcal disease in a medium-sized community in the United States. JAMA. 1982 Sep 24;248(12):1486–1489. [PubMed] [Google Scholar]
- Patrick K. M., Woolley F. R. A cost-benefit analysis of immunization for pneumococcal pneumonia. JAMA. 1981 Feb 6;245(5):473–477. [PubMed] [Google Scholar]
- Reichek N., Lewin E. B., Rhoden D. L., Weaver R. R., Crutcher J. C. Antibody responses to bacterial antigens during exacerbations of chronic bronchitis. Am Rev Respir Dis. 1970 Feb;101(2):238–244. doi: 10.1164/arrd.1970.101.2.238. [DOI] [PubMed] [Google Scholar]
- Rozanski J. J., Kleinfeld M. Exercise-induced ST segment alternans. Chest. 1984 Apr;85(4):582–583. [PubMed] [Google Scholar]
- Ruben F. L., Norden C. W., Korica Y. Pneumococcal bacteremia at a medical/surgical hospital for adults between 1975 and 1980. Am J Med. 1984 Dec;77(6):1091–1094. doi: 10.1016/0002-9343(84)90193-1. [DOI] [PubMed] [Google Scholar]
- Ruben F. L., Uhrin M. Specific immunoglobulin-class antibody responses in the elderly before and after 14-valent pneumococcal vaccine. J Infect Dis. 1985 May;151(5):845–849. doi: 10.1093/infdis/151.5.845. [DOI] [PubMed] [Google Scholar]
- Williams J. H., Jr, Moser K. M. Pneumococcal vaccine and patients with chronic lung disease. Ann Intern Med. 1986 Jan;104(1):106–109. doi: 10.7326/0003-4819-104-1-106. [DOI] [PubMed] [Google Scholar]